CA-MOVEWORKS
22.2.2024 21:01:33 CET | Business Wire | Press release
Moveworks, the leading AI copilot platform for the enterprise, today announced registration for its annual Moveworks.global conference is now open. The event will take place on April 23, 2024, and will be held both virtually and in-person in San Jose, CA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222535446/en/
In an era where artificial intelligence is not just an advantage but a necessity, Moveworks.global is the must-attend event for industry leaders, developers, and forward-thinkers eager to explore the transformative power of generative AI in business. This event serves as a dynamic platform for participants to engage with the brightest minds in the industry.
With past speakers from world-renowned companies like OpenAI, Salesforce, Honeywell, and more, attendees will learn firsthand how best-in-class organizations are leveraging generative AI to foster unprecedented levels of business agility. From global corporations to smaller enterprises eager to harness the potential of generative AI, Moveworks.global promises to offer invaluable insights for leveraging AI to gain a competitive edge.
Event highlights include:
- Unlocking productivity: Discover the untapped potential of centralizing search and action to streamline operations while enhancing productivity.
- AI adaptability through reasoning: Learn why advanced AI reasoning capabilities are crucial for creating adaptable, intelligent systems that can meet evolving business needs.
- Custom AI solutions: Gain practical knowledge on customizing AI tools to align with specific business processes — accelerating growth and innovation.
- Continuous improvement: Hear success stories and proven strategies from various industries on driving continuous service improvement through AI.
Whether you're aiming to integrate AI into your organization or develop AI-driven solutions, Moveworks.global will open new horizons and inspire actionable strategies for leveraging generative AI within the enterprise.
“Moveworks.global is more than just a conference — it's a catalyst for transformative change with AI,” said Bhavin Shah, CEO and founder of Moveworks. “This year, we're zeroing in on tangible generative AI successes, showcasing actual outcomes and practical frameworks from industry pioneers. It's a unique opportunity to learn from those who've turned their AI visions into reality.”
Join us at Moveworks.global to be at the forefront of the AI revolution in business. Register today to secure your place among leaders pioneering the future of enterprise AI.
For more information and to register, visit: https://global.moveworks.com/2024.
About Moveworks
Moveworks is the leading AI copilot platform for the enterprise. It empowers the workforce to interact with and take action across all business systems through natural language. Powered by the world’s most advanced LLMs and our proprietary MoveLM model, the Moveworks copilot enables users to search information, take action, automate tasks, and generate factually accurate content with generative AI. Companies such as Databricks, Broadcom, Hearst, and Toyota North America leverage Moveworks' out-of-the-box solutions and intuitive developer tools to automate L1 support, enhance the employee experience, and accelerate business transformation.
Founded in 2016, Moveworks has raised $315 million in funding, at a valuation of $2.1 billion. In 2023, it was named to the Forbes Cloud 100 list — a definitive list of the top private cloud companies in the world — and has been included in Forbes’ AI 50 list for five consecutive years.
For more information, visit: Moveworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222535446/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom